Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

EU flag

EU Parliament panel backs updated clinical trials regulations

But pharma industry concerned about measures to increase transparency

- PMLiVE

Amgen boosts Japan prospects with Astellas partnership

Companies establish joint venture and plan to co-develop new medicines

Amgen and Novartis partner with biotech venture capital firm

Atlas Venture fund aims to create 15 new biotech companies

- PMLiVE

Amgen forms joint venture in China to boost Vectibix

Partners with Zhejiang Beta Pharma on colon cancer drug

- PMLiVE

Global biosimilars market to reach $2.45bn in 2013

And EMA plans to revise its guidelines for the area

- PMLiVE

AbbVie gets ‘breakthrough’ status for hepatitis C regimen

Combination could be all-oral alternative to injectable interferon alpha-based therapies

- PMLiVE

Arena pulls obesity drug Belviq application in EU

EMA asks for more data

- PMLiVE

Court blocks EMA release of pharma company data

AbbVie and InterMune successfully challenge request for trial data for Humira and Esbriet

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

AbbVie said to be planning major salesforce cuts in US

Follows loss of patent protection for TriCor and Niaspan

Unfolding the biosimilar landscape in Latin America

Cost containment and safety concerns mean an ongoing tussle between payers and regulators, with the latter gaining the upper hand

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links